Russia says data shows Sputnik 95% effective and prices vaccine at under $20
Moscow claims its Covid-19 vaccine is cheaper and more effective than similar rivals, but scientists question its safety
Moscow — Russia's Sputnik-V Covid-19 vaccine will cost under $20 per person on international markets and Moscow aims to produce more than a billion doses at home and abroad next year, its financial backers and developers said on Tuesday.
The Sputnik vaccine, named after the Soviet-era satellite that triggered the space race in a nod to the project's geopolitical importance for Moscow, is administered in two shots, each of which will cost less than $10, according to the official Sputnik-V Twitter account.
For Russian citizens, inoculation will be free of charge. Mass vaccination in Russia, which has the world's fifth-highest number of recorded Covid-19 cases, has yet to begin as phase 3 clinical trials continue.
The Kremlin said on Tuesday that President Vladimir Putin had not been vaccinated with Sputnik-V. His position meant he could not take something that was still being tested, it said. One of his two daughters had taken it however, Putin disclosed in August, and felt fine afterwards.
Russia's pricing announcement comes as Russia looks to scale up distribution and production and as three vaccines, one by Oxford/AstraZeneca, another by Pfizer/BioNTech and a third by Moderna, have emerged in the West, raising hopes that the global pandemic can be tamed in 2021.
Moscow, keen to win global market share, touted the international price for Sputnik-V as competitive.
“It's more than twice as cheap as other vaccines that have the same efficacy levels,” Kirill Dmitriev, head of Russia's RDIF sovereign wealth fund, told a briefing.
“Right now, Sputnik-V is the cheapest vaccine with an efficacy level above 90% in phase 3 clinical trials”.
The price of the Russian vaccine is cheaper than some other western rivals such as the vaccine produced by Pfizer, which costs €15.5 per shot, but more expensive than the vaccine developed by AstraZeneca and the University of Oxford, which will be sold in Europe for about €2.5 per shot.
Russia plans to produce about 2-million doses of Sputnik-V in 2020, and Dmitriev said Moscow and its foreign partners had capacity to make more than a billion doses starting from next year, enough to vaccinate more than 500-million people.
More than 50 countries had made requests for more than 1.2-billion doses, he said. Supplies for the global market would be produced by partners in India, Brazil, China, South Korea, Hungary and other countries.
Production of a new freeze-dried form of the vaccine, which means it can be stored in a fridge and is easier to distribute, was also under way, he said, something he said he believed would make it attractive for countries in Africa and Asia.
Talks were also ongoing with other foreign partners on increasing production, he added.
RDIF and the Gamaleya National Centre said earlier on Tuesday that new clinical trial data based on 39 confirmed cases and 18,794 patients who had both shots had shown that Sputnik-V was 91.4% effective on day 28 and over 95% effective on day 42.
That's well above the 50% effectiveness threshold for Covid-19 vaccines set by the US. Food and Drug Administration.
The data would be published in a leading scientific journal next month for experts to scrutinise, Dmitriev promised.
The phase 3 trial of the shot is taking place in 29 clinics across Moscow and will involve 40,000 volunteers in total, with a quarter receiving a placebo shot.
Russia's health-care system is under heavy strain, the Kremlin said on Tuesday, as authorities reported a record 491 deaths linked to Covid-19 and infections surged.
Russia has been criticised by some scientists in the West who have accused it of cutting corners in an effort to try to rush out the vaccine and complained about the amount of data available to allow others to interpret its research.
In particular, some Western scientists have criticised Moscow for giving the regulatory go-ahead for the shot and launching mass vaccinations before full trials had been completed.
Russia has rejected such criticism and insisted that it is doing everything safely and responsibly. It alleges a Western smear campaign to put people off its vaccine in what it believes has become a battle for legitimacy and market share.
Dmitriev on Tuesday praised Western success at developing vaccines, saying the world would need different vaccines. He said Russia was ready to share its know-how with manufacturers such as AstraZeneca if helpful.
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.